Phase II Study to Evaluate the Tumor Biochemical Effects of the EGFR Tyrosine Kinase Inhibitor OSI-774 (Erlotinib) Administered Prior to Surgical Resection in Patients With Early Stage Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2013
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Mar 2012 Planned end date 1 Apr 2006 added as reported by ClinicalTrials.gov.